Is AOD-9604 Legal in South Carolina? How to Access It Legally

What Is AOD-9604 and Why Does Its Status Matter?

AOD-9604 is a synthetic peptide fragment derived from amino acids 176 to 191 of human growth hormone (hGH). Researchers initially investigated it for fat metabolism and obesity treatment. The compound stimulates lipolysis and inhibits lipogenesis through mechanisms that appear to be independent of the insulin-like growth factor 1 (IGF-1) axis, which raised hopes that it could produce weight-loss effects without the adverse metabolic profile associated with full-length hGH.

The regulatory history shapes every conversation about legal access. Metabolic Pharmaceuticals Ltd. Conducted Phase II and Phase III human clinical trials under the brand name AOD9604, and the compound received FDA Investigational New Drug (IND) status for obesity [1]. The New Drug Application was ultimately not approved, leaving AOD-9604 in a post-trial limbo: it has documented human safety data but no approved clinical indication in the United States [2].

Why the Regulatory Gray Zone Exists

The absence of FDA approval does not automatically make a compound illegal to prescribe. US drug law, specifically 21 USC 353a and 353b, permits licensed pharmacies to compound drugs from bulk active pharmaceutical ingredients (APIs) under defined conditions [3]. AOD-9604 sits in a contested position on those lists, and understanding the distinction between 503A and 503B compounding is the first step toward knowing what a South Carolina patient can lawfully access.

How AOD-9604 Differs From Scheduled Substances

AOD-9604 is not a controlled substance under the Controlled Substances Act (CSA). The DEA has not scheduled it, and possession for personal use does not carry the criminal penalties attached to Schedule I or II compounds [4]. That distinction matters for South Carolina residents, because the legal risks here are regulatory (invalid compounding, practicing medicine without a license, importation violations) rather than criminal drug-possession charges.

The Federal Regulatory Framework That Governs South Carolina Access

Federal law is the dominant layer for peptide access anywhere in the United States. States can add restrictions on top of federal rules; they cannot remove them.

FDA's 503A vs. 503B Compounding Distinction

The Drug Quality and Security Act of 2013 created two compounding pathways [3]:

• 503A pharmacies are traditional compounding pharmacies that prepare drugs for individual patients pursuant to a valid prescription. They are licensed at the state level and operate under state pharmacy board oversight, with the FDA retaining authority over the bulk substances they may use.
• 503B outsourcing facilities are federally registered facilities that can produce larger batches without individual prescriptions. They are subject to current Good Manufacturing Practice (cGMP) standards and may only compound from bulk substances the FDA has specifically nominated and reviewed.

AOD-9604 appears on the FDA's list of bulk drug substances that have been evaluated but were not placed on the 503B Category 1 approved list. The FDA's Memorandum on Difficult-to-Compound Drugs and the associated Federal Register notices classify AOD-9604 as a substance for which there is insufficient evidence of clinical need to justify 503B compounding [5]. This means no 503B outsourcing facility may legally compound AOD-9604 for distribution.

What 503A Allows

The 503A pathway is narrower but remains available. A 503A pharmacy may compound AOD-9604 if the following conditions are met:

1. A licensed practitioner has issued a patient-specific prescription based on a genuine patient-provider relationship.
2. The compounded preparation is not essentially a copy of a commercially available FDA-approved drug (no approved AOD-9604 product exists, so this condition is easily met).
3. The API used meets USP or other applicable standards, typically sourced from an FDA-registered API manufacturer.
4. The pharmacy does not advertise or promote the specific compounded drug to the general public in a way that circumvents the prescription requirement.

The FDA has signaled that it is scrutinizing peptide compounding broadly. A 2023 FDA guidance document on compounded peptides noted that many peptides have not been adequately evaluated for safety and efficacy when compounded, and the agency continues to assess which bulk substances warrant 503A use [6]. Prescribers and pharmacies operating in this space are subject to ongoing regulatory review.

Research-Use-Only (RUO) AOD-9604 Is Not for Human Use

A significant share of the AOD-9604 circulating online is sold as a "research chemical" or "for laboratory use only." These products are not manufactured under pharmaceutical-grade conditions, carry no quality guarantees, and cannot legally be administered to humans. Purchasing RUO peptides and self-injecting them is not a protected activity under 503A or any other compounding exemption. The FDA has taken enforcement action against vendors selling RUO peptides with implied clinical use [7].

South Carolina-Specific Rules and Oversight Bodies

South Carolina does not have a state statute that specifically names AOD-9604 or enumerates a list of restricted peptides beyond what federal law provides. Legal access is therefore governed by the intersection of federal compounding rules and South Carolina's existing pharmacy and medical practice statutes.

South Carolina Board of Pharmacy

The South Carolina Board of Pharmacy licenses and regulates all pharmacies operating in the state, including compounding pharmacies. South Carolina Code of Laws, Title 40, Chapter 43 (the Pharmacy Practice Act) requires that compounding pharmacies comply with USP standards (specifically USP Chapters 795 and 797 for non-sterile and sterile preparations) and with applicable federal law [8]. Because AOD-9604 is typically administered via subcutaneous injection, any compounded preparation must meet USP 797 sterility standards, which require specific clean-room infrastructure and beyond-use dating protocols.

A compounding pharmacy in South Carolina that produces AOD-9604 without a valid patient-specific prescription, or that sources the API from a non-FDA-registered supplier, would be operating in violation of both state pharmacy law and federal compounding law simultaneously.

South Carolina Medical Practice Act

Under South Carolina Code of Laws, Title 40, Chapter 47, physicians licensed by the South Carolina Board of Medical Examiners may prescribe any legal substance within the scope of their medical judgment and professional practice [9]. There is no South Carolina statute that explicitly prohibits a physician from prescribing a compounded peptide. The legal standard applied is whether the prescription was issued in the course of a legitimate professional relationship, for a legitimate medical purpose, and in conformity with accepted professional standards.

Prescribing AOD-9604 off-label is legally permissible. Physicians have broad authority to prescribe compounded drugs off-label, and the FDA's off-label prescribing policy explicitly preserves this right [10]. The practical risk for a South Carolina prescriber is professional rather than criminal: a board complaint alleging prescribing outside acceptable standards of care.

Telehealth Prescribing in South Carolina

South Carolina allows telehealth prescribing for many medications, including compounded drugs, provided that a valid provider-patient relationship has been established. The South Carolina Department of Labor, Licensing and Regulation has issued guidance confirming that telehealth visits satisfy the patient-provider relationship requirement for prescribing purposes, provided the prescriber is licensed in South Carolina and the clinical encounter meets documentation standards [11]. This means patients may obtain an AOD-9604 prescription through a South Carolina-licensed telehealth provider without an in-person visit, so long as a thorough medical evaluation is conducted and documented.

The Clinical Evidence Base for AOD-9604

Understanding the evidence helps patients and prescribers assess whether AOD-9604 is a clinically reasonable option, separate from its legal status.

Phase II and Phase III Trial History

Metabolic Pharmaceuticals conducted three Phase II dose-ranging trials in obese adults. In one 12-week randomized controlled trial (N=300), participants receiving AOD-9604 at 1 mg/day lost an average of 2.1 kg more than placebo, a statistically significant finding at the time [1]. A subsequent 24-week Phase IIb trial (N=492) showed modest but measurable reductions in body fat percentage compared with placebo. The Phase III program was initiated but the FDA ultimately declined to approve the NDA, in part because the Phase III data did not replicate the Phase II effect sizes with the statistical power required for approval [2].

Mechanism and Preclinical Findings

In rodent models, AOD-9604 at doses of 0.25 mg/kg to 1 mg/kg administered subcutaneously for 4 weeks produced dose-dependent reductions in fat mass without measurable effects on blood glucose or IGF-1 levels [12]. This IGF-1 independence is the pharmacological argument prescribers most commonly cite for AOD-9604 over recombinant hGH in weight-management contexts. That preclinical distinction has not been definitively replicated in adequately powered human trials.

What the Evidence Does and Does Not Support

The available evidence is sufficient to conclude that AOD-9604 is not overtly toxic in short-term human use at the doses studied. It is not sufficient to support a claim that it produces clinically meaningful, durable weight loss in the general population. Prescribers citing the 2007 Australian clinical data should note that those participants were adults with BMI between 27 and 35, that the primary endpoint was change in body weight over 12 weeks, and that the effect sizes were modest by modern obesity-pharmacology standards. For comparison, semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo (P<0.001) [13], a substantially larger effect than anything demonstrated in AOD-9604 trials.

As the Endocrine Society's 2022 Clinical Practice Guideline on Pharmacological Management of Obesity notes, "anti-obesity medications should be used as part of a comprehensive lifestyle intervention and only when the benefits outweigh the potential risks for the individual patient" [14]. AOD-9604 is not among the medications evaluated in that guideline, which underscores the off-label nature of any clinical use.

How to Access AOD-9604 Legally in South Carolina

The only legally defensible route to AOD-9604 in South Carolina is through a licensed South Carolina prescriber writing a patient-specific prescription, dispensed by a licensed 503A compounding pharmacy. The steps are concrete.

Step 1: Establish Care With a Licensed South Carolina Prescriber

This may be an in-person appointment or a telehealth visit with a provider licensed in South Carolina. The provider must conduct a clinical evaluation adequate to justify the prescription. That evaluation should include at minimum: a review of weight history, metabolic labs (fasting glucose, lipid panel, thyroid function), current medications, and a documented discussion of the limited evidence base and the experimental nature of the treatment.

Patients should be cautious of online "clinics" that issue prescriptions after a two-minute questionnaire. South Carolina's Board of Medical Examiners can sanction prescribers for failing to establish an adequate patient-provider relationship before prescribing.

Step 2: Confirm the Pharmacy Is a Licensed 503A Compounder

Ask the prescribing clinic which pharmacy they work with and verify that pharmacy's licensure independently. The National Association of Boards of Pharmacy (NABP) maintains a database of state-licensed and accredited compounding pharmacies. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation as an additional quality marker. The pharmacy should be able to provide a Certificate of Analysis (CoA) from the API supplier and documentation that the sterile preparation met USP 797 standards.

Step 3: Understand the Prescription and Dosing

Compounded AOD-9604 is typically prepared as a lyophilized powder reconstituted with bacteriostatic water for subcutaneous injection. Doses in the clinical trials ranged from 500 mcg to 1 mg per day. The prescription should specify the concentration, volume per injection, frequency, and total quantity dispensed. Patients should receive written instructions on reconstitution, injection technique, storage (typically 2 to 8 degrees Celsius after reconstitution), and beyond-use dating.

Step 4: Ongoing Monitoring

Any clinician prescribing AOD-9604 should schedule follow-up appointments at 4 to 8 week intervals to assess response, tolerability, and any emerging concerns. There are no FDA-mandated monitoring parameters for AOD-9604 given the absence of approval, but reasonable clinical practice mirrors the monitoring used in compounded peptide programs generally: weight, body composition if available, fasting glucose, and patient-reported side effects.

What to Avoid: Red Flags in the AOD-9604 Market

The unregulated peptide market is large and growing. South Carolina residents searching for AOD-9604 will find dozens of websites selling vials labeled "for research use only" at prices that undercut licensed pharmacy compounding costs. These sources carry serious risks.

• RUO vials are not manufactured under pharmaceutical cGMP conditions. A 2020 analysis of commercially available research peptides found that 44% of samples contained the labeled peptide at less than 90% of stated purity, and some contained detectable bacterial endotoxins [7].
• Importing peptides from overseas sources without an FDA import permit violates the Federal Food, Drug, and Cosmetic Act. US Customs and Border Protection regularly seizes such shipments.
• Self-administering an unprescribed injectable substance removes any legal protection and any avenue for recourse if adverse effects occur.

The FDA's Office of Criminal Investigations has pursued criminal charges against vendors selling peptides with implied human use claims, and several such cases have resulted in federal convictions under 21 USC 331 (prohibited acts) [7].

Comparing Legal Peptide Access Pathways in South Carolina

| Pathway | Legal for AOD-9604? | Requires Prescription? | Quality Assurance | |---|---|---|---| | 503A compounding pharmacy | Yes, with valid Rx | Yes | State board oversight, USP 797 | | 503B outsourcing facility | No | N/A | Not applicable | | FDA-approved finished drug | No (none exists) | N/A | Not applicable | | Research chemical / RUO vendor | No for human use | No | None | | International online pharmacy | No (import violation) | Varies | None |